Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

This study has been completed.
SCRI Development Innovations, LLC
Information provided by (Responsible Party):
MEI Pharma, Inc. Identifier:
First received: February 22, 2012
Last updated: June 17, 2015
Last verified: April 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2014
  Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)